Ranexa 375 mg, 500 mg, 750 mg Prolonged-release tablets
PDF Leaflet Revision Date: 26 August 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Symptomatic treatment of stable angina pectoris as add-on therapy.
Dosage (summary)
Initial: 375 mg twice daily, titrate to 500 mg, max 750 mg twice daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
- Low weight
- Congestive heart failure
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- CYP3A4 inhibitors
- P-glycoprotein inhibitors
- CYP3A4 inducers
Contraindications
- Hypersensitivity to ranolazine
- Severe renal impairment
- Moderate or severe hepatic impairment
- Potent CYP3A4 inhibitors
- Class Ia and III antidysrhythmics
Common side effects
- Dizziness
- Nausea
- Constipation
- Vomiting
- Headache
Counselling Points
- Take whole, do not crush.
- Monitor for dizziness and nausea.
- Report any unusual symptoms.
Serious warnings
- QT prolongation risk
- Increased exposure in certain populations
Important Disclaimer
The Ranexa 375 mg, 500 mg, 750 mg Prolonged-release tablets professional information leaflet below is the property of Menarini South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
